You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis

Authors

  • Siming Li Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Xiaowen Wu Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Xieqiao Yan Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Li Zhou Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Zhihong Chi Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Lu Si Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Chuanliang Cui Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Bixia Tang Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Lili Mao Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Bin Lian Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Xuan Wang Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Xue Bai Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Jie Dai Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Yan Kong Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Xiongwen Tang Medical Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaMedical Department, TopAlliance Biosciences, Inc, Rockville, Maryland, USA PubMed articlesGoogle scholar articles
  • Hui Feng Medical Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaMedical Department, TopAlliance Biosciences, Inc, Rockville, Maryland, USA PubMed articlesGoogle scholar articles
  • Sheng Yao Medical Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, ChinaMedical Department, TopAlliance Biosciences, Inc, Rockville, Maryland, USA PubMed articlesGoogle scholar articles
  • Keith T Flaherty Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Jun Guo Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles
  • Xinan Sheng Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China PubMed articlesGoogle scholar articles

Citation

Li S, Wu X, Yan X, et al
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
Journal for ImmunoTherapy of Cancer 2022;10:e004036. doi: 10.1136/jitc-2021-004036
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.